Key result
Silencing the TLR4 gene significantly decreased CVB3-induced TLR4 production and lessened the severity of viral myocarditis in a mouse model.
Why the study?
Does silencing the TLR4 gene ameliorate coxsackievirus B3-induced viral myocarditis in a mouse model?
Does silencing the TLR4 gene ameliorate coxsackievirus B3-induced viral myocarditis in a mouse model?
Silencing the TLR4 gene ameliorates CVB3-induced viral myocarditis in a mouse model, suggesting TLR4 as a potential therapeutic target for viral myocarditis.
Hypothesis-generating for TLR4 targeting in viral myocarditis; leaves open translation beyond mouse models.
In the present study, we investigated the potential pathogenesis of coxsackievirus B3 (CVB3)-induced viral myocarditis and the promising protective effect of silencing RNA (small interfering RNA, siRNA). One hundred and twenty mice were included in the study, and 30 mice were intraperitoneally inoculated with CVB3 to establish an acute viral myocarditis model. The survival rate was observed for the CVB3-infected mouse model (MOD), and myocardial injury was examined by HE (hematoxylin and eosin) staining assay. Real-time PCR (RT-PCR) and Western blot assay were selected to detect the toll-like receptor 4 (TLR4) expression in myocardial tissues. The TLR4 gene was silenced for the MOD mice, and the effects of this treatment were observed. The results indicate that the expression of TLR4 mRNA and the protein significantly and persistently increased during the progression of CVB3-induced myocarditis. The activities of cardiac enzymes including CK, LDH, AST, and CK-MB were also enhanced in CVB3-induced myocardial tissues. Interestingly, when the TLR4 gene was silenced, the CVB3-induced TLR4 production was significantly decreased and the severity of myocarditis was significantly lessened. In conclusion, CVB3 may induce viral myocarditis by upregulating toll-like receptor 4 expression. The viral myocarditis can be ameliorated by silencing the TLR4 gene in the CVB3 viral myocarditis model, which may be a feasible therapeutic method for treatment of viral myocarditis.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2015) studied Acute viral myocarditis (n=120). Silencing RNA (siRNA) targeting TLR4 gene vs. CVB3-infected mouse model without silencing was evaluated on TLR4 expression, myocardial injury, and cardiac enzymes. Silencing the TLR4 gene significantly decreased CVB3-induced TLR4 production and lessened the severity of viral myocarditis in a mouse model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: